{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:45:19Z","timestamp":1793659519866,"version":"4.5.1"},"reference-count":29,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Introduction: Metabolic Dysfunction-associated Liver Disease (MASLD) represents a spectrum of conditions from simple fat accumulation to non-alcoholic steatohepatitis. The possible role of the intestinal microbiome on MASLD development has been in focus. Our study aimed to examine the effects of synbiotics on the liver steatosis, inflammation, and stool microbiome.<\/jats:p>\n                  <jats:p>\n                    Methods: A double-blind, placebo-controlled study was conducted involving 84 MASLD patients, defined by an elastometric attenuation coefficient (ATT) greater than 0.63 dB\/cm\/MHz with an alanine aminotransferase level above 40 U\/L for men and 35 U\/L for women. The patients were divided into an intervention group treated with a synbiotic with 64x10\n                    <jats:sup>9<\/jats:sup>\n                    CFU of\n                    <jats:italic>Lactobacillus<\/jats:italic>\n                    and\n                    <jats:italic>Bifidobacterium<\/jats:italic>\n                    and 6.4g of inulin and a control group treated with a placebo.\n                  <\/jats:p>\n                  <jats:p>\n                    Results: Using synbiotics for 12 weeks significantly decreased liver steatosis (\u0394ATT -0.006\u00b10.023 vs -0.016\u00b10.021 dB\/cm\/MHz, p=0.046). The group of patients treated with synbiotics showed a significant decrease in the level of high-sensitive C-reactive protein (\u0394hs-CRP 0 vs -0.7 mg\/L, p\u22640.001). Synbiotics enriched the microbiome of patients in the intervention group with the genera\n                    <jats:italic>Lactobacillus, Bifidobacterium, Faecalibacterium<\/jats:italic>\n                    , and\n                    <jats:italic>Streptococcus<\/jats:italic>\n                    , by 81%, 55%, 51%, and 40%, respectively, with a reduction of\n                    <jats:italic>Ruminococcus<\/jats:italic>\n                    and\n                    <jats:italic>Enterobacterium<\/jats:italic>\n                    by 35% and 40%. Synbiotic treatment significantly shortened the gut transition time (\u0394GTT -5h vs. -10h, p=0.031).\n                  <\/jats:p>\n                  <jats:p>Conclusion: Synbiotics could be an effective and safe option that could have place in MASLD treatment.<\/jats:p>","DOI":"10.2478\/rjim-2024-0004","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T07:07:51Z","timestamp":1709190471000},"page":"184-193","source":"Crossref","is-referenced-by-count":17,"title":["The effects of synbiotics on the liver steatosis, inflammation, and gut microbiome of metabolic dysfunction-associated liver disease patients-randomized trial"],"prefix":"10.2478","volume":"62","author":[{"given":"Milo\u0161","family":"Mitrovi\u0107","sequence":"first","affiliation":[{"name":"Clinical Department for Gastroenterology and Hepatology , University Medical Center Zvezdara- Dimitrija Tucovi\u0107a Street 161 , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Dobrosavljevi\u0107","sequence":"additional","affiliation":[{"name":"Clinical Department for Gastroenterology and Hepatology , University Medical Center Zvezdara- Dimitrija Tucovi\u0107a Street 161 , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Odanovi\u0107","sequence":"additional","affiliation":[{"name":"Clinical Department for Gastroenterology and Hepatology , University Medical Center Zvezdara- Dimitrija Tucovi\u0107a Street 161 , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Kne\u017eevi\u0107-Ivanovski","sequence":"additional","affiliation":[{"name":"Clinical Department for Gastroenterology and Hepatology , University Medical Center Zvezdara- Dimitrija Tucovi\u0107a Street 161 , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0110or\u0111e","family":"Kralj","sequence":"additional","affiliation":[{"name":"Clinical Department for Gastroenterology and Hepatology , University Medical Center Zvezdara- Dimitrija Tucovi\u0107a Street 161 , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Erceg","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Belgrade University - Department of Medical Biochemistry , Vojvode Stepe Street 450 , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Peru\u0107ica","sequence":"additional","affiliation":[{"name":"Microbiology Department , University Medical Center Zvezdara - Belgrade , Serbia, Pre\u0161evska Street 31, 11000 Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Svorcan","sequence":"additional","affiliation":[{"name":"Clinical Department for Gastroenterology and Hepatology , University Medical Center Zvezdara- Dimitrija Tucovi\u0107a Street 161 , Belgrade , Serbia"},{"name":"Faculty of Medicine , Belgrade University , dr Suboti\u0107a Street 8, 11000 Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verica","family":"Stankovi\u0107-Popovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , Belgrade University , dr Suboti\u0107a Street 8, 11000 Belgrade , Serbia"},{"name":"Nephrology Clinic , University Clinical Center , Pasterova Street 2 , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"2026042913134231707_j_rjim-2024-0004_ref_001","doi-asserted-by":"crossref","unstructured":"1. BURT AD., LACKNER C., TINIAKOS D. Diagnosis and Assessment of MASLD: Definitions and Histopathological Classification. Semin Liver Dis. 2015; 35:207-20.","DOI":"10.1055\/s-0035-1562942"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_002","doi-asserted-by":"crossref","unstructured":"2. WONG RJ., AGUILAR M., CHEUNG R., PERUMPAIL RB., HARRISON SA., YOUNOSSI ZM., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015; 148:547-55.","DOI":"10.1053\/j.gastro.2014.11.039"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_003","doi-asserted-by":"crossref","unstructured":"3. BOURSIER J., DIEHL AM. Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease. PLoS Pathog. 2015; 11: e1004559.","DOI":"10.1371\/journal.ppat.1004559"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_004","doi-asserted-by":"crossref","unstructured":"4. VAJRO P., PAOLELLA G., FASANO A. Microbiota and gut-liver axis: A mini-review on their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2013; 56:461\u2013468.","DOI":"10.1097\/MPG.0b013e318284abb5"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_005","doi-asserted-by":"crossref","unstructured":"5. ZHOU X., WANG J., ZHOU S., LIAO J., YE Z., MAO L. Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis. Medicine (Baltimore). 2023;102:e32734.","DOI":"10.1097\/MD.0000000000032734"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_006","doi-asserted-by":"crossref","unstructured":"6. JUNGERSEN M., WIND A., JOHANSEN E., CHRISTENSEN JE., STUER-LAURIDSEN B., ESKESEN D. The Science behind the Probiotic Strain Bifidobacterium animalis subsp. lactis BB-12(\u00ae). Microorganisms. 2014; 2:92-110.","DOI":"10.3390\/microorganisms2020092"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_007","doi-asserted-by":"crossref","unstructured":"7. OU Y., CHEN S., REN F., ZHANG M., GE S., GUO H.,et al. Lactobacillus casei Strain Shirota Alleviates Constipation in Adults by Increasing the Pipecolinic Acid Level in the Gut. Front Microbiol. 2019;10:324.","DOI":"10.3389\/fmicb.2019.00324"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_008","doi-asserted-by":"crossref","unstructured":"8. KOIZUMI Y., HIROOKA M., TAMAKI N., YADA N., NAKASHIMA O., IZUMI N., et al. New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode. PLoS One. 2019;14:e0221548.","DOI":"10.1371\/journal.pone.0221548"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_009","doi-asserted-by":"crossref","unstructured":"9. CAPORASO JG., LAUBER CL., WALTERS WA., BERG-LYONS D., HUNTLEY J., FIERER N., et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISMEJ. 2012; 6:1621-4.","DOI":"10.1038\/ismej.2012.8"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_010","doi-asserted-by":"crossref","unstructured":"10. EDGAR RC. UPARSE: Highly Accurate OTU Sequences from Microbial Amplicon Reads. Nat Methods. 2013. 1: 996\u20138.","DOI":"10.1038\/nmeth.2604"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_011","doi-asserted-by":"crossref","unstructured":"11. DIMEN\u00c4S E., CARLSSON G., GLISE H., ISRAELSSON B., WIKLUND I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl. 1996; 221:8-13.","DOI":"10.3109\/00365529609095544"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_012","doi-asserted-by":"crossref","unstructured":"12. ASNICAR F., LEEMING ER., DIMIDI E., MAZIDI M., FRANKS PW., AL KHATIB H., et al. Blue poo: impact of gut transit time on the gut microbiome using a novel marker. Gut. 2021;70:1665-74.","DOI":"10.1136\/gutjnl-2020-323877"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_013","unstructured":"13. Raosoft Software. Calculate Your Sample Size. http:\/\/www.raosoft.com\/samplesize.html Date accessed 3rd January 2021."},{"key":"2026042913134231707_j_rjim-2024-0004_ref_014","doi-asserted-by":"crossref","unstructured":"14. AHN SB., JUN DW., KANG BK., LIM JH., LIM S., CHUNG MJ. Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease. Sci Rep. 2019; 9:5688.","DOI":"10.1038\/s41598-019-42059-3"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_015","doi-asserted-by":"crossref","unstructured":"15. Bomhof MR., Parnell JA., Ramay HR., Crotty P., Rioux KP., Probert CS., et al. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. Eur J Nutr. 2019; 58:1735-1745.","DOI":"10.1007\/s00394-018-1721-2"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_016","doi-asserted-by":"crossref","unstructured":"16. Duseja A., Acharya SK., Mehta M., Chhabra S., Shalimar., Rana S., et al. High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (MASLD): a randomised, double-blind, proof of concept study. BMJ Open Gastroenterol. 2019; 6:e000315.","DOI":"10.1136\/bmjgast-2019-000315"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_017","doi-asserted-by":"crossref","unstructured":"17. Kobyliak N., Abenavoli L., Mykhalchyshyn G., Kononenko L., Boccuto L., Kyriienko D., et al. A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in MASLD Patients: Evidence from a Randomized Clinical Trial. J Gastrointestin Liver Dis. 2018; 27:41-9.","DOI":"10.15403\/jgld.2014.1121.271.kby"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_018","doi-asserted-by":"crossref","unstructured":"18. MCFARLANE C., RAMOS CI., JOHNSON DW., CAMPBELL KL. Prebiotic, Probiotic, and Synbiotic Supplementation in Chronic Kidney Disease: A Systematic Review and Meta-analysis. J Ren Nutr. 2019; 29:209-220.","DOI":"10.1053\/j.jrn.2018.08.008"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_019","doi-asserted-by":"crossref","unstructured":"19. ARAI N, MIURA K, AIZAWA K, SEKIYA M, NAGAYAMA M, SAKAMOTO H, et al. (2022). Probiotics suppress nonalcoholic steatohepatitis and carcinogenesis progression in hepatocyte-specific PTEN knockout mice. Scientific Reports 2022; 12: 1-12.","DOI":"10.1038\/s41598-022-20296-3"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_020","doi-asserted-by":"crossref","unstructured":"20. HENKE MT, KENNY DJ, CASSILLY CD, VLAMAKIS H, XAVIER RJ, CLARDY J. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn's disease, produces an inflammatory polysaccharide. Proc Natl Acad Sci U S A 2019; 116:12672-7.","DOI":"10.1073\/pnas.1904099116"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_021","doi-asserted-by":"crossref","unstructured":"21. BALDELLI V., SCALDAFERRI F., PUTIGNANI L., DEL CHIERICO F. The Role of Enterobacteriaceae in Gut Microbiota Dysbiosis in Inflammatory Bowel Diseases. Microorganisms. 2021; 9:697.","DOI":"10.3390\/microorganisms9040697"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_022","doi-asserted-by":"crossref","unstructured":"22. NAGPAL R., SHIVELY CA., REGISTER TC., CRAFT S., YADAV H. Gut microbiome-Mediterranean diet interactions in improving host health. F1000Res. 2019; 8:699.","DOI":"10.12688\/f1000research.18992.1"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_023","doi-asserted-by":"crossref","unstructured":"23. LEE G., YOU HJ., BAJAJ JS., JOO SK., YU J., PARK S., et al. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese MASLD. Nat Commun 2020; 11:4982.","DOI":"10.1038\/s41467-020-18754-5"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_024","doi-asserted-by":"crossref","unstructured":"24. ROMAN\u00cd-P\u00c9REZ M., L\u00d3PEZ-ALMELA I., BULLICH-VILARRUBIAS C., RUEDA-RUZAFA L., G\u00d3MEZ DEL PULGAR EM., BEN\u00cdTEZ-P\u00c1EZ A., et al. Holdemanella biformis improves glucose tolerance and regulates GLP-1 signaling in obese mice. FASEB J. 2021; 35:e21734.","DOI":"10.1096\/fj.202100126R"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_025","doi-asserted-by":"crossref","unstructured":"25. NEWSOME PN., BUCHHOLTZ K., CUSI K., LINDER M., OKANOUE T., RATZIU V., et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021; 384:1113-1124.","DOI":"10.1056\/NEJMoa2028395"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_026","doi-asserted-by":"crossref","unstructured":"26. GUDAN A., JAMIO\u0141-MILC D., HAWRY\u0141KOWICZ V., SKONIECZNA-\u017bYDECKA K., STACHOWSKA E. The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: MASLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression. Nutrients 2022; 14:5261.","DOI":"10.3390\/nu14245261"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_027","doi-asserted-by":"crossref","unstructured":"27. TAKAKURA W, PIMENTEL M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome - An Update. Front Psychiatry 2020;11:664.","DOI":"10.3389\/fpsyt.2020.00664"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_028","doi-asserted-by":"crossref","unstructured":"28. SCHATTENBERG JM. Intestinal motility: a therapeutic target for MASLD? Lancet Gastroenterol Hepatol. 2020; 5:957-958.","DOI":"10.1016\/S2468-1253(20)30204-1"},{"key":"2026042913134231707_j_rjim-2024-0004_ref_029","doi-asserted-by":"crossref","unstructured":"29. KESSOKU T., IMAJO K., KOBAYASHI T., OZAKI A., IWAKI M., HONDA Y., et al. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol. 2020; 5:996-1007.","DOI":"10.1016\/S2468-1253(20)30216-8"}],"container-title":["Romanian Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/rjim-2024-0004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:13:22Z","timestamp":1777486402000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/rjim-2024-0004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,7]]},"published-print":{"date-parts":[[2024,6,1]]}},"alternative-id":["10.2478\/rjim-2024-0004"],"URL":"https:\/\/doi.org\/10.2478\/rjim-2024-0004","relation":{},"ISSN":["2501-062X"],"issn-type":[{"value":"2501-062X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]}}}